Monday, September 15, 2025
No Result
View All Result
The Financial Observer
  • Home
  • Business
  • Economy
  • Stocks
  • Markets
  • Investing
  • Crypto
  • PF
  • Startups
  • Forex
  • Fintech
  • Real Estate
  • Analysis
  • Home
  • Business
  • Economy
  • Stocks
  • Markets
  • Investing
  • Crypto
  • PF
  • Startups
  • Forex
  • Fintech
  • Real Estate
  • Analysis
No Result
View All Result
The Financial Observer
No Result
View All Result
Home Business

‘Modern day snake-oil salesman’: The Liver Doc clashes with Bryan Johnson over ‘anti-ageing’ Blueprint

‘Modern day snake-oil salesman’: The Liver Doc clashes with Bryan Johnson over ‘anti-ageing’ Blueprint
Share on FacebookShare on Twitter


Bryan Johnson, an American entrepreneur, is famend for his anti-ageing programme referred to as Blueprint, which entails a plant-based food regimen, common train, and an in depth array of dietary supplements. 

Johnson claims his routine will reverse organic ageing and has led to biomarkers similar to these of an 18-year-old. Now, Dr Cyriac Abby Philips, a hepatologist from Kerala, has brazenly criticised Blueprint, drawing parallels between Johnson and notorious fraudsters like Elizabeth Holmes and Belle Gibson. 

Dr Philips, often called ‘The Liver Doc’, accuses Johnson of promoting overpriced and unverified dietary supplements. In keeping with Philips, Blueprint is a dangerous enterprise, devoid of considerable scientific backing. “It’s terrifying that folks don’t see Bryan Johnson as truly a well-evolved masculine type of fraudsters Elizabeth Holmes and Belle Gibson, promoting each costly and completely ineffective investigations and peddling probably harmful snake oil dietary supplements within the title of BLUEPRINT,” Dr Philips commented. 

In defence, Johnson insists his merchandise are reputable, stating all parts have “vitamins which have unbiased and sturdy scientific proof.” He additional claims they’re third-party examined, with publically out there certificates of study. 

“Blueprint provides further virgin olive oil, proteins, nuts, and vitamins which have unbiased and sturdy scientific proof. They’re third-party examined. The certificates of study are publically out there. They’re affordably priced,” Johnson asserted. 

Nonetheless, Dr Philips demanded scientific proof and dosage specifics, which he alleges Johnson has not supplied. 

The shortage of large-scale research on the security and interplay of drugs utilized in Blueprint raises further considerations, Dr Philips warns. He additionally flags potential unintended effects from the interplay of varied botanical extracts. 

Howdy @bryan_johnson, I’ve posted rational and logical questions relating to your BluePrint which I’ve gone by means of, and as scientific physician and a scientific researcher discovered it to be a rip-off.I do know precisely what I’m speaking about and do. I’m a Physician of Drugs. You might verify… https://t.co/T9h3jVnfOH

— TheLiverDoc (@theliverdr) March 31, 2025

Regardless of these points, Johnson contends his private well being enhancements are proof of Blueprint’s efficacy, although Dr Philips argues private anecdotes are usually not substitutes for scientific proof. 

Johnson, beforehand embroiled in disputes regarding office behaviour, has responded to Dr Philips’ critiques with questions concerning the physician’s motives, asking, “Cyriac why are you so indignant? Who harm you?” 

Nevertheless, Dr Philips stays resolute, regularly difficult Johnson to offer scientific validation for Blueprint’s claims. With out such proof, Philips suggests the programme stays speculative and probably deceptive for customers.  



Source link

Tags: anti-ageingantiageingBelle GibsonbiomarkersBlueprintbotanical extractsBryanBryan Johnsonclashesclinical evidenceconsumer safetydayDocDr Cyriac Abby PhilipsElizabeth HolmesJohnsonLiverModernpersonal healthplant-based dietsafety concernsSalesmanscientific evidencescientific validationscientific validitysnakeoilsupplementsThe Liver Doc
Previous Post

Barista FIRE at 36 with ONLY $500K by Trading “Stuff” for Substance

Next Post

Terminal 1 reopening revives Israel low-cost fare options

Related Posts

Vail Resorts Now Has a 6% Dividend Yield. Time to Buy the Stock?
Business

Vail Resorts Now Has a 6% Dividend Yield. Time to Buy the Stock?

September 14, 2025
Rs 32,000 crore festive IPO boom? LG Electronics, Tata Capital to test investor appetite this Diwali
Business

Rs 32,000 crore festive IPO boom? LG Electronics, Tata Capital to test investor appetite this Diwali

September 14, 2025
Poland scrambles jets, shuts key airport amid drone threat
Business

Poland scrambles jets, shuts key airport amid drone threat

September 13, 2025
Calamos U.S. Convertible Strategy Q2 2025 Commentary
Business

Calamos U.S. Convertible Strategy Q2 2025 Commentary

September 12, 2025
Infosys board gives nod to Rs 18,000-crore share buyback
Business

Infosys board gives nod to Rs 18,000-crore share buyback

September 12, 2025
Light rail boosts Jaffa home prices
Business

Light rail boosts Jaffa home prices

September 11, 2025
Next Post
Terminal 1 reopening revives Israel low-cost fare options

Terminal 1 reopening revives Israel low-cost fare options

Eurozone Inflation at 4-Month Low, DAX Rises as Rate Cut Bets Intensifies

Eurozone Inflation at 4-Month Low, DAX Rises as Rate Cut Bets Intensifies

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest
The Stock Market Just Did Something for the 16th Time Since 1950. It Usually Signals a Big Move in the Next Year.

The Stock Market Just Did Something for the 16th Time Since 1950. It Usually Signals a Big Move in the Next Year.

August 19, 2025
In praise of complicated investing strategies

In praise of complicated investing strategies

August 19, 2025
SEC and Ripple officially settle appeals, XRP case moves to final enforcement

SEC and Ripple officially settle appeals, XRP case moves to final enforcement

August 22, 2025
If your chart is showing AUD/USD around 0.6630, get outta here! Pair trading around 0.6647

If your chart is showing AUD/USD around 0.6630, get outta here! Pair trading around 0.6647

September 14, 2025
The Division Of The United States Is In Motion

The Division Of The United States Is In Motion

September 14, 2025
Vail Resorts Now Has a 6% Dividend Yield. Time to Buy the Stock?

Vail Resorts Now Has a 6% Dividend Yield. Time to Buy the Stock?

September 14, 2025
How AI is Decoding Investor Psychology in Real-Time: A Deep Dive into Behavioural Finance for Fintech Innovators

How AI is Decoding Investor Psychology in Real-Time: A Deep Dive into Behavioural Finance for Fintech Innovators

September 14, 2025
Metaverse Is Rising Again – Records +13K NFT Users In August

Metaverse Is Rising Again – Records +13K NFT Users In August

September 15, 2025
Planning to retire in 2045 as a 30 years old with VOO, does this math make sense? : personalfinance

Planning to retire in 2045 as a 30 years old with VOO, does this math make sense? : personalfinance

September 14, 2025
The Financial Observer

Get the latest financial news, expert analysis, and in-depth reports from The Financial Observer. Stay ahead in the world of finance with up-to-date trends, market insights, and more.

Categories

  • Business
  • Cryptocurrency
  • Economy
  • Fintech
  • Forex
  • Investing
  • Market Analysis
  • Markets
  • Personal Finance
  • Real Estate
  • Startups
  • Stock Market
  • Uncategorized

Latest Posts

  • If your chart is showing AUD/USD around 0.6630, get outta here! Pair trading around 0.6647
  • The Division Of The United States Is In Motion
  • Vail Resorts Now Has a 6% Dividend Yield. Time to Buy the Stock?
  • About Us
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2025 The Financial Observer.
The Financial Observer is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Business
  • Economy
  • Stocks
  • Markets
  • Investing
  • Crypto
  • PF
  • Startups
  • Forex
  • Fintech
  • Real Estate
  • Analysis

Copyright © 2025 The Financial Observer.
The Financial Observer is not responsible for the content of external sites.